minimum investment: $504.00
Saving lives with AI and specialized MRI
According to the American Urology Association, Prostate cancer costs the United States an estimated $11.5 billion every year. Medicare alone reports spending $1.2 billion over a three year period. These staggering figures only include the costs for medical care and does not account of the intangible costs of lost wages, caregiving, and even the funeral expenses patients and their families incur. We believe ProstatID will help reduce these high costs for patients, providers, and taxpayers.
By using ProstatID for the early detection of prostate cancer, physicians will be able to catch cancer earlier and provide more affordable treatment options. In fact, on average, the treatments available for early stage prostate cancer cost 2 to 4 times less than treatments available at more advanced stages. If adopted as the new standard of medical care, we believe ProstatID has the potential save the United States billions.
Funding target: $10,000 – $1,070,000 by 9/3/2019
Regulation CF: Equity (Common stock)
Minimum investment: $504